Recursion Pharmaceuticals earnings were -$574.8M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest RXRX earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$202.5M, up 13.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, RXRX reported annual earnings of -$463.7M, with 41.3% growth.
Recursion Pharmaceuticals Earnings Reports & History FAQ
What were Recursion Pharmaceuticals's earnings last quarter?
On RXRX's earnings call on Invalid Date, Recursion Pharmaceuticals (NASDAQ: RXRX) reported Q1 2025 earnings per share (EPS) of -$0.50, up 28.21% year over year. Total RXRX earnings for the quarter were -$202.49 million. In the same quarter last year, Recursion Pharmaceuticals's earnings per share (EPS) was -$0.39.
Is Recursion Pharmaceuticals profitable or losing money?
As of the last Recursion Pharmaceuticals earnings report, Recursion Pharmaceuticals is currently losing money. Recursion Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$574.78 million, a 62.31% increase year over year.
What was RXRX's earnings growth in the past year?
As of Recursion Pharmaceuticals's earnings date in Invalid Date, Recursion Pharmaceuticals's earnings has grown year over year. RXRX earnings in the past year totalled -$574.78 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.